TMPO-AS1 and laryngeal squamous cell carcinoma: Lastly, TMPO‐AS1, identified as a novel molecular participant in the progression of laryngeal squamous cell carcinoma (LSCC), not only contributes to the disease's pathogenic pathways but also holds potential as a viable prognostic biomarker, offering insights into the future direction of LSCC diagnostics and therapy.23